Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Financial Officer | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 164,096 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 3,000 · Balance 164,096 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 12, 2025 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,916 | $117.30 | $576,640.90 |
DisclosureSEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,074 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · price: Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 13,013 | $63.91 | $831,660.83 |
DisclosureSEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,916 | $63.91 | $314,181.56 |
DisclosureSEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $104.09 | $260,225.00 |
DisclosureSEC source: 0001127602-25-005525 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,061 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 18,210 | $0.00 Strike: $83.49 | $0.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · derivative · entry 9 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,210 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $80.72 | $0.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · derivative · entry 8 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,600 shares Expires 2028-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 26,175 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · derivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,515 Underlying: Common Stock · 26,175 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 77,691 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,929 Underlying: Common Stock · 77,691 shares Expires 2031-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 137,676 | $102.22 | $14,073,240.72 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,223 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 18,210 | $83.49 | $1,520,352.90 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,600 | $80.72 | $1,259,232.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26,175 | $57.92 | $1,516,056.00 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 02:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 77,691 | $63.91 | $4,965,231.81 |
DisclosureSEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 43,138 | $97.99 | $4,227,092.62 |
DisclosureSEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,223 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 64,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,361 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2022. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,666 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 44,160 | $0.00 Strike: $65.38 | $0.00 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · derivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,160 shares Expires 2029-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,850 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 26,170 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,690 Underlying: Common Stock · 26,170 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 142,180 | $97.22 | $13,822,739.60 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,873 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · price: Sales prices reported for the transactions reported here range from $97.22 to $97.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 44,160 | $65.38 | $2,887,180.80 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 273,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 71,850 | $72.34 | $5,197,629.00 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26,170 | $57.92 | $1,515,766.40 |
DisclosureSEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 20:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $91.35 | $228,375.00 |
DisclosureSEC source: 0001127602-25-001321 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,873 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,500 | $91.96 | $781,660.00 |
DisclosureSEC source: 0001127602-24-029638 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,373 F1 · kind: The transaction reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029165 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,487 Underlying: Common Stock · 3,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,686 | $92.34 | $155,685.24 |
DisclosureSEC source: 0001127602-24-029165 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,873 Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029165 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 65,960 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 14 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,960 shares Expires 2026-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 43,340 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 13 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,340 shares Expires 2027-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F5 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 60,885 | $0.00 Strike: $71.91 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 12 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,885 shares Expires 2028-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 33,660 | $0.00 Strike: $68.75 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 11 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,660 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 18,630 | $0.00 Strike: $73.77 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 10 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,630 shares Expires 2027-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F5 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 26,170 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · derivative · entry 9 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,860 Underlying: Common Stock · 26,170 shares Expires 2032-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 127,930 | $92.76 | $11,867,119.42 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 8 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,919 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F3 · price: Sales prices reported for the transactions reported here range from $92.33 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 120,715 | $92.77 | $11,198,151.12 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,849 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 · price: Sales prices reported for the transactions reported here range from $92.36 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 65,960 | $72.70 | $4,795,292.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 43,340 | $72.70 | $3,150,818.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,885 | $71.91 | $4,378,240.35 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 33,660 | $68.75 | $2,314,125.00 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26,170 | $57.92 | $1,515,766.40 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 19:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 18,630 | $73.77 | $1,374,335.10 |
DisclosureSEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,127 Underlying: Common Stock · 3,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,682 | $81.44 | $136,982.08 |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,919 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,768 Underlying: Common Stock · 3,639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,662 | $65.25 | $108,445.50 |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,960 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 00:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 17,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009540 · form4.xml · derivative · entry 7 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,407 Underlying: Common Stock · 17,305 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 00:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 87,970 | $0.00 Strike: $75.12 | $0.00 |
DisclosureSEC source: 0001127602-24-009540 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,970 Underlying: Common Stock · 87,970 shares Expires 2034-03-10 F5 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.